| Literature DB >> 35924979 |
Anna Yeaton1,2, Geraldine Cayanan1,2, Iannis Aifantis1,2, Maria Guillamot1,2, Sanam Loghavi3, Igor Dolgalev4, Emmett M Leddin5,6, Christian E Loo7, Hedieh Torabifard5,6, Deedra Nicolet8,9, Jingjing Wang1,2, Kate Corrigan1,2, Varvara Paraskevopoulou1,2, Daniel T Starczynowski10,11,12, Eric Wang13, Omar Abdel-Wahab13, Aaron D Viny14,15,16, Richard M Stone17, John C Byrd18, Olga A Guryanova19, Rahul M Kohli7, G Andrés Cisneros5,6, Aristotelis Tsirigos4, Ann-Kathrin Eisfeld8,20.
Abstract
Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated preleukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation frequently found in patients with CH and leukemia. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid leukemia (AML). Using single-cell transcriptomic profiling of the bone marrow, we show that disease progression in aged animals correlates with an enhanced inflammatory response and the emergence of an aberrant inflammatory monocytic cell population. The gene signature characteristic of this inflammatory population is associated with poor prognosis in patients with AML. Our study illustrates an example of collaboration between a genetic lesion found in CH and inflammation, leading to transformation and the establishment of blood neoplasms. SIGNIFICANCE: Progression from a preleukemic state to transformation, in the presence of TET2 mutations, is coupled with the emergence of inflammation and a novel population of inflammatory monocytes. Genes characteristic of this inflammatory population are associated with the worst prognosis in patients with AML. These studies connect inflammation to progression to leukemia. See related commentary by Pietras and DeGregori, p. 2234 . This article is highlighted in the In This Issue feature, p. 2221. ©2022 American Association for Cancer Research.Entities:
Mesh:
Year: 2022 PMID: 35924979 PMCID: PMC9547930 DOI: 10.1158/2159-8290.CD-21-1146
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 38.272